Verapamil HCl
别名: CP-16533-1, (±)-Verapamil 中文名称：盐酸维拉帕米
Verapamil HCl是L-型钙通道抑制剂，是第四类抗心律失常的药剂。Verapamil 可抑制 permeability-glycoprotein (P-gp) 和 CYP3A4。
Verapamil HCl Chemical Structure
CAS: 152-11-4
产品质控
批次：
纯度：
99.98%
99.98
Verapamil HCl相关产品
相关信号通路图
细胞实验数据示例
| 细胞系 | 实验类型 | 给药浓度 | 孵育时间 | 活性描述 | 文献信息 |
|---|---|---|---|---|---|
| MCF7/VP | Function assay | 20 uM | 48 hrs | Inhibition of MRP expressed in human MCF7/VP cells assessed as increase in vincristine-induced cytotoxicity at 20 uM after 48 hrs by SRB binding assay | 8786364 |
| human MCF7/ADR cells | Function assay | 10 μM | 48 h | Inhibition of P-gp in human MCF7/ADR cells assessed as reversal of multidrug resistance at 10 uM by measuring EC50 for adriamycin-induced cytotoxicity after 48 hrs by SRB colorimetric assay, EC50=4.89 μM | 25856545 |
| KB-3-1 | Cytotoxicity assay | 5 uM | 68 hrs | Reversal of P-gp-mediated multidrug resistance to Cytotoxicity of colchicine against human KB-3-1 cells at 5 uM after 68 hrs by MTT assay, IC50=0.0047μM | 17488128 |
| KB-C2 | Cytotoxicity assay | 5 uM | 68 hrs | Reversal of P-gp-mediated multidrug resistance to Cytotoxicity of colchicine against human KB-C2 cells at 5 uM after 68 hrs by MTT assay, IC50=0.1μM | 17488128 |
| MDCK2 | Function assay | 10 uM | 40 mins | Inhibition of human wild type Pgp expressed in MDCK2 cells assessed as calcein-AM accumulation at 10 uM after 40 mins | 17964170 |
| PC12 | Autophagy assay | 1 uM | 24 hrs | Induction of autophagy in rat stable inducible PC12 cells expressing A53T alpha-synuclein assessed as A53T alpha-synuclein clearance at 1 uM after 24 hrs by densitometric analysis | 18391949 |
| PC12 | Autophagy assay | 1 uM | 96 hrs | Induction of autophagy in rat stable inducible PC12 cells expressing EGFP-HDQ74 assessed as soluble EGFP-HDQ74 clearance at 1 uM after 96 hrs by densitometric analysis | 18391949 |
| SK-N-MC | Autophagy assay | 1 uM | 48 hrs | Induction of autophagy in human SK-N-MC cells expressing EGFP-HDQ74 assessed as reduction in EGFP-HDQ74 aggregation at 1 uM after 48 hrs by densitometric analysis | 18391949 |
| SK-N-MC | Autophagy assay | 0.33 uM | 24 hrs | Induction of autophagy in human SK-N-MC cells assessed as increase in LC3-2 level at 0.33 uM after 24 hrs by immunoblotting analysis | 18391949 |
| SK-N-MC | Autophagy assay | 1 uM | 48 hrs | Induction of autophagy in Atg positive human SK-N-MC cells expressing EGFP-HDQ74 at 1 uM after 48 hrs | 18391949 |
| PC12 | Autophagy assay | 1 uM | 24 hrs | Induction of autophagy in pretreated rat stable inducible PC12 cells expressing EGFP-HDQ74 assessed as calpain activation at 1 uM followed by doxycyline treatment measured after 24 hrs | 18391949 |
| SK-N-SH | Autophagy assay | 1 uM | 48 hrs | Induction of autophagy in human SK-N-SH cells expressing EGFP-HDQ74 assessed as inhibition of Bay K8644-induced EGFP-HDQ74 aggregation at 1 uM after 48 hrs | 18391949 |
| RBMEC | Function assay | 10 umol/L | 90 mins | Inhibition of Pgp-mediated multidrug resistance activity in rat RBMEC cells assessed as Rh123 accumulation at 10 umol/L after 90 mins | 18502125 |
| K562 | Function assay | 1 uM | 72 hrs | Potentiation of doxorubicin-induced growth inhibition in human doxorubicin-resistant K562 cells expressing Pgp at 1 uM after 72 hrs by MTT assay | 19140665 |
| K562 | Function assay | 3 uM | 72 hrs | Potentiation of doxorubicin-induced growth inhibition in human doxorubicin-resistant K562 cells expressing Pgp at 3 uM after 72 hrs by MTT assay | 19140665 |
| MDCK | Function assay | 30 uM | 1.5 hrs | Inhibition of human MDR1 expressed in MDCK cells assessed as fluorescence activity at 30 uM after 1.5 hrs by rhodamine 123 efflux test | 20363635 |
| NIH-3T3 | Function assay | 10 uM | 30 mins | Inhibition of human MDR1 expressed in mouse NIH-3T3 cells assessed as daunomycin efflux at 10 uM after 30 mins by flow cytometry | 21856049 |
| Caco2 | Function assay | 5 to 25 uM | 1.5 hrs | Inhibition of P-glycoprotein overexpressed in human Caco2 cells assessed as increase in digoxin accumulation at 5 to 25 uM incubated for 1.5 hrs prior to digoxin treatment measured after 1.5 hrs by LC/MS/MS analysis | 22209486 |
| K562/A02 | Function assay | 10 uM | 24 hrs | Reversal of p-glycoprotein-mediated multidrug-resistant in human K562/A02 cells assessed as increase of adriamycin-induced cytotoxic effect at 10 uM treated for 24 hrs followed by adriamycin treated 6 hrs after drug washout by MTS assay, IC50=26.06μM | 22405646 |
| K562/A02 | Function assay | 0.25 to 5 after | 60 mins | Inhibition of p-glycoprotein-mediated rhodamine 123 efflux in human K562/A02 cells at 0.25 to 5 after 60 mins by fluorescence microscopic analysis | 22405646 |
| K562/A02 | Function assay | 10 uM | 30 mins | Inhibition of Pgp-mediated rhodamine 123 efflux in human K562/A02 cells assessed as intracellular rhodamine 123 accumulation at 10 uM preincubated for 30 mins measured after 60 mins by fluorescence microscopy relative to control | 22429509 |
| K562/A02 | Function assay | 10 uM | 24 hrs | Inhibition of P-glycoprotein in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity at 10 uM preincubated for 24 hrs followed by washout before addition of adriamycin measured after 72 hrs by MTS assay (Rvb = 33.59 uM) | 22429509 |
| K562/A02 | Function assay | 10 uM | 24 hrs | Inhibition of P-glycoprotein in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity at 10 uM preincubated for 24 hrs followed by washout addition of adriamycin at 6 hrs post washout measured after 72 hrs by MTS assay (Rvb = 35 | 22429509 |
| K562/A02 | Function assay | 10 uM | 24 hrs | Inhibition of P-glycoprotein in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity at 10 uM preincubated for 24 hrs followed by washout addition of adriamycin at 12 hrs post washout measured after 72 hrs by MTS assay (Rvb = 5 | 22429509 |
| K562/A02 | Function assay | 10 uM | 24 hrs | Inhibition of P-glycoprotein in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity at 10 uM preincubated for 24 hrs followed by washout addition of adriamycin at 24 hrs post washout measured after 72 hrs by MTS assay (Rvb = 5 | 22429509 |
| K562/A02 | Function assay | 0.33 to 10 uM | 60 mins | Inhibition of Pgp-mediated rhodamine-123 efflux in multidrug-resistance human K562/A02 cells assessed as increase in intracellular accumulation of rhodamine-123 at 0.33 to 10 uM after 60 mins by flow cytometry analysis | 22450134 |
| K562/A02 | Function assay | 0.33 to 10 uM | 60 mins | Inhibition of Pgp-mediated rhodamine-123 efflux in multidrug-resistance human K562/A02 cells assessed as increase in intracellular accumulation of rhodamine-123 at 0.33 to 10 uM after 60 mins by fluorescence microscopic analysis | 22450134 |
| K562/A02 | Function assay | 0.33 to 10 uM | 60 mins | Inhibition of Pgp-mediated adriamycin efflux in multidrug-resistance human K562/A02 cells assessed as increase in intracellular accumulation of adriamycin at 0.33 to 10 uM after 60 mins by FACS flow cytometry | 22450134 |
| KBVIN | Function assay | 10 uM | 72 hrs | Inhibition of P-gp-mediated multidrug-resistance in human KBVIN cells assessed as paclitaxel-induced cytotoxicity at 10 uM after 72 hrs by SRB assay | 22612652 |
| KBVIN | Function assay | 10 uM | 72 hrs | Inhibition of P-gp-mediated multidrug-resistance in human KBVIN cells assessed as vincristine-induced cytotoxicity at 10 uM after 72 hrs by SRB assay | 22612652 |
| KBVIN | Function assay | 10 uM | 72 hrs | Inhibition of P-gp-mediated multidrug-resistance in human KBVIN cells assessed as doxorubicin-induced cytotoxicity at 10 uM after 72 hrs by SRB assay | 22612652 |
| KB/VCR | Function assay | 5 uM | 72 hrs | Inhibition of p-gp in human KB/VCR cells assessed as potentiation of adriamycin-induced cytotoxicity at 5 uM after 72 hrs by MTT assay | 23683834 |
| KB/VCR | Function assay | 5 uM | 72 hrs | Inhibition of p-gp in human KB/VCR cells assessed as potentiation of vincristine-induced cytotoxicity at 5 uM after 72 hrs by MTT assay | 23683834 |
| MDCK | Function assay | 100 uM | 2 hrs | Activation of ATPase activity of MDR1 (unknown origin) expressed in MDCK cells assessed as reduction of reduction of ATP level at 100 uM after 2 hrs by luminescence/ATPlite assay | 24607999 |
| NCI-H292 | Cytotoxicity assay | 50 uM | 72 hrs | Potentiation of gefitinib-induced cytotoxicity against human NCI-H292 cells assessed as gefitinib IC50 at 50 uM after 72 hrs by SRB assay, IC50=0.18μM | 25215856 |
| NCI-H292 | Cytotoxicity assay | 50 uM | 72 hrs | Potentiation of erlotinib-induced cytotoxicity against human NCI-H292 cells assessed as erlotinib IC50 at 50 uM after 72 hrs by SRB assay, IC50=1.2μM | 25215856 |
| H460 | Cytotoxicity assay | 50 uM | 72 hrs | Potentiation of erlotinib-induced cytotoxicity against human H460 cells assessed as erlotinib IC50 at 50 uM after 72 hrs by SRB assay, IC50=10.3μM | 25215856 |
| H460/Vbl | Cytotoxicity assay | 50 uM | 72 hrs | Potentiation of erlotinib-induced cytotoxicity against human H460/Vbl cells assessed as erlotinib IC50 at 50 uM after 72 hrs by SRB assay, IC50=13.3μM | 25215856 |
| H460 | Cytotoxicity assay | 50 uM | 72 hrs | Potentiation of gefitinib-induced cytotoxicity against human H460 cells assessed as gefitinib IC50 at 50 uM after 72 hrs by SRB assay, IC50=19.6μM | 25215856 |
| H460/Vbl | Cytotoxicity assay | 50 uM | 72 hrs | Potentiation of gefitinib-induced cytotoxicity against human H460/Vbl cells assessed as gefitinib IC50 at 50 uM after 72 hrs by SRB assay, IC50=25.7μM | 25215856 |
| K562 | Function assay | 3 uM | 72 hrs | Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562 cells at 3 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 0.023 +/- 0.004 uM), IC50=0.029μM | 25282263 |
| K562/DOX | Function assay | 3 uM | 72 hrs | Modulatory activity at P-gp assessed as doxorubicin IC50 in human K562/DOX cells at 3 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 2.00 +/- 0.24 uM), IC50=0.74μM | 25282263 |
| K562/ADR | Function assay | 10 uM | 2.5 hrs | Increase in adriamycin uptake in human K562/ADR cells at 10 uM after 2.5 hrs by fluorescence microscopy | 25462264 |
| K562/ADR | Function assay | 10 uM | 2.5 hrs | Increase in adriamycin uptake in human K562/ADR cells at 10 uM after 2.5 hrs by fluorescence spectrophotometry | 25462264 |
| K562/ADR | Cytotoxicity assay | 10 uM | 48 hrs | Potentiation of adriamycin-induced cytotoxicity against human K562/ADR cells at 10 uM after 48 hrs by MTT assay | 25462264 |
| K562/A02 | Function assay | 5 uM | 48 hrs | Reversal of P-gp-mediated multidrug resistance in human K562/A02 cells assessed as reduction of adriamycin IC50 at 5 uM after 48 hrs by MTT assay, IC50=6.8μM | 25464884 |
| K562/A02 | Function assay | 5 uM | 24 hrs | Reversal of P-gp-mediated multidrug resistance in human K562/A02 cells assessed as reduction of adriamycin IC50 at 5 uM incubated for 24 hrs prior to adriamycin treatment measured after 48 hrs by MTT assay, IC50=9.6μM | 25464884 |
| K562/A02 | Function assay | 2.5 uM | 48 hrs | Reversal of P-gp-mediated multidrug resistance in human K562/A02 cells assessed as reduction of adriamycin IC50 at 2.5 uM after 48 hrs by MTT assay, IC50=15.92μM | 25464884 |
| K562/A02 | Function assay | 5 uM | 24 hrs | Reversal of P-gp-mediated multidrug resistance in human K562/A02 cells assessed as reduction of adriamycin IC50 at 5 uM incubated for 24 hrs followed by adriamycin treatment post compound washout measured after 48 hrs by MTT assay, IC50=40.8μM | 25464884 |
| KB/VCR | Cytotoxicity assay | 25 uM | 72 hrs | Cytotoxicity against human KB/VCR cells assessed as vincristine IC50 at 25 uM after 72 hrs by SRB method, IC50=0.02μM | 25597010 |
| K562/R7 | Cytotoxicity assay | 1 uM | 72 hrs | Potentiation of doxorubicin-induced cytotoxicity against doxorubicin-resistant human K562/R7 cells assessed as doxorubicin IC50 at 1 uM after 72 hrs by MTT assay, IC50=0.6μM | 25634041 |
| MDA435/LCC6MDR | Function assay | 1 uM | 5 days | Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversible of paclitaxel resistance measured as IC50 for paclitaxel at 1 uM after 5 days by CellTiter 96 Aqueous assay, IC50=0.038μM | 25985195 |
| MDA435/LCC6MDR | Function assay | 3 uM | 150 mins | Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as restoration of intracellular doxorubicin accumulation at 3 uM after 150 mins by spectrofluorometric analysis relative to parental cells | 25985195 |
| MCF7/D70 | Function assay | 10 uM | 72 hrs | Inhibition of P-gp in human MCF7/D70 cells assessed as decrease in doxorubicin IC50 at 10 uM after 72 hrs by MTT assay (Rvb doxorubicin alone IC50 = 0.906 +/- 0.02 uM), IC50=0.2μM | 26840362 |
| K562/A02 | Function assay | 5 uM | 48 hrs | Reversal of P-gp-mediated resistance to adriamycin in human K562/A02 cells assessed as adriamycin IC50 at 5 uM after 48 hrs by MTT assay (Rvb = 38.02 +/- 1.65 uM), IC50=8.5μM | 27073052 |
| K562/A02 | Function assay | 2.5 uM | 48 hrs | Reversal of P-gp-mediated resistance to adriamycin in human K562/A02 cells assessed as adriamycin IC50 at 2.5 uM after 48 hrs by MTT assay (Rvb = 38.02 +/- 1.65 uM), IC50=19.84μM | 27073052 |
| MDA435/LCC6MDR | Function assay | 1 uM | 5 days | Inhibition of P-gp in human MDA435/LCC6MDR cells assessed as potentiation of paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 1 uM measured after 5 days by Cell Titer 96 Aqueous assay (Rvb = 139.3 +/- 7.5 nM), IC50=0.0351μM | 27750197 |
| K562 | Function assay | 10 uM | 1 hr | Inhibition of P-gp in doxorubicin resistant human K562 cells assessed as increase in accumulation of rhodamine 123 at 10 uM measured after 1 hr by flow cytometry | 27908756 |
| K562/A02 | Function assay | 0.33 to 10 uM | 1 hr | Inhibition of P-gp in human K562/A02 cells assessed as increase in intracellular rhodamine123 accumulation at 0.33 to 10 uM measured after 1 hr by flow cytometry | 28068095 |
| LoVo/DX | Function assay | 2.5 to 10 uM | 15 mins | Inhibition of P-gp in human LoVo/DX cells assessed as reduction in Rhodamine123 efflux at 2.5 to 10 uM preincubated for 15 mins followed by Rhodamine123 addition measured after 1 hr by flow cytometry | 28109950 |
| LoVo/DX | Function assay | 10 uM | 2 hrs | Substrate activity at P-gp in human LoVo/DX cells assessed as ATP consumption at 10 uM after 2 hrs by ATPlite assay | 28109950 |
| MCF7/DX | Function assay | 5 uM | 48 hrs | Reversal of multidrug resistance in human MCF7/DX cells assessed as potentiation doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 level at 5 uM incubated for 48 hrs by MTT assay, IC50=6.59μM | 28245113 |
| K562/A02 | Function assay | 5 uM | 2.5 hrs | Inhibition of ABCB1 in human K562/A02 cells assessed as increase in intracellular adriamycin accumulation at 5 uM after 2.5 hrs by spectrofluorimetric analysis | 28301155 |
| K562/A02 | Function assay | 5 uM | up to 90 mins | Inhibition of ABCB1 in human K562/A02 cells assessed as increase in intracellular Rh123 accumulation at 5 uM up to 90 mins by flow cytometry | 28301155 |
| K562/A02 | Function assay | 5.0 uM | up to 90 mins | Inhibition of P-gp mediated efflux in human K562/A02 cells assessed as intracellular Rh123 accumulation at 5.0 uM measure up to 90 mins by flow cytometric analysis | 28355069 |
| K562/A02 | Function assay | 5 uM | 24 hrs | Inhibition of P-gp in human K562/A02 cells assessed as potentiation of doxorubicin-induced cytotoxicity at 5 uM preincubated for 24 hrs followed by doxorubicin addition measured after 48 hrs by MTT assay | 28355069 |
| K562/A02 | Function assay | 5.0 uM | 150 mins | Inhibition of P-gp in human K562/A02 cells assessed as accumulation of doxorubicin at 5.0 uM after 150 mins by fluorescence spectrophotometric analysis | 28355069 |
| K562/A02 | Function assay | 5 uM | 48 hrs | Inhibition of ABCB1 in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring ADR IC50 at 5 uM measured after 48 hrs by MTT assay (Rvb = 43.75 to 96.91 uM), IC50=17.55μM | 28645831 |
| K562/A02 | Function assay | 0.5 to 2.5 uM | 60 mins | Inhibition of ABCB1 in human K562/A02 cells assessed as increase in adriamycin accumulation at 0.5 to 2.5 uM pretreated for 60 mins followed by ADR addition after 90 mins by fluorescence spectrophotometric method | 28645831 |
| SW620/AD300 | Function assay | 2 uM | 30 to 120 mins | Inhibition of ABCB1 in human SW620/AD300 cells assessed as reduction in Rh123 efflux at 2 uM treated followed by Rh123 addition in Rh123 free medium for 30 to 120 mins by flow cytometry | 29126726 |
| MCF7/ADR | Function assay | 10 uM | 4 hrs | Inhibition of P-gp mediated efflux in human MCF7/ADR cells at 10 uM after 4 hrs by Rh123 dye-based flow cytometric method | 29407947 |
| K562/A02 | Function assay | 5 uM | 2.5 hrs | Inhibition of P-gp in human K562/A02 cells assessed as increase in adriamycin accumulation at 5 uM after 2.5 hrs by flow cytometry method | 29631786 |
| K562 | Function assay | 5 uM | 2.5 hrs | Inhibition of P-gp in human K562 cells assessed as increase in Rh123 accumulation at 5 uM after 2.5 hrs by by flow cytometry method | 29631786 |
| MCF7/ADR | Function assay | 10 uM | 2 hrs | Inhibition of P-gp in human MCF7/ADR cells assessed as increase in intracellular Rh123 accumulation at 10 uM after 2 hrs by flow cytometry | 29903663 |
| MCF7 | Cytotoxicity assay | 10 ug/ml | 48 hrs | Potentiation of adriamycin-induced cytotoxicity in human MCF7 cells assessed as adriamycin IC50 at 10 ug/ml after 48 hrs by MTT assay (Rvb = 1.3 +/- 0.2 uM), IC50=1.5μM | 30137985 |
| MCF7/ADR | Function assay | 10 ug/ml | 24 hrs | Inhibition of P-gp in human MCF7/ADR cells assessed as increase in intracellular accumulation of adriamycin by measuring increase in fluorescence intensity at 10 ug/ml after 24 hrs by fluorescence microscopic analysis | 30137985 |
| KBV | Function assay | 10 uM | 72 hrs | Reversal of P-gp-mediated multidrug resistance in human KBV cells assessed as potentiation of paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 10 uM after 72 hrs by MTT assay (Rvb = 1353.98 +/- 303.33 nM), IC50=0.02816μM | 30347326 |
| KBV | Function assay | 10 uM | 2 hrs | Inhibition of P-gp-mediated Rh-123 efflux in human KBV cells assessed as Rh-123 accumulation at 10 uM preincubated for 2 hrs followed by Rh-123 addition measured after 30 mins by flow cytometry | 30347326 |
| KBV | Function assay | 10 uM | 72 hrs | Reversal of P-gp-mediated drug resistance in human KBV cells assessed as potentiation of paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 10 uM after 72 hrs by MTT assay (Rvb = 398.34 +/- 0.58 uM), IC50=6.15μM | 30384042 |
| KBV | Cytotoxicity assay | 10 uM | 48 hrs | Potentiation of vincristine-induced cytotoxicity against human KBV cells assessed as vincristine IC50 at 10 uM after 48 hrs by MTT assay (Rvb = 666.3 nM), IC50=0.00131μM | 30455148 |
| A2780/TAX | Cytotoxicity assay | 10 uM | 48 hrs | Potentiation of paclitaxel-induced cytotoxicity against human A2780/TAX cells assessed as paclitaxel IC50 at 10 uM after 48 hrs by MTT assay (Rvb = 3970 nM), IC50=0.0188μM | 30455148 |
| A2780/CDDP | Cytotoxicity assay | 10 uM | 48 hrs | Potentiation of cisplatin-induced cytotoxicity against human A2780/CDDP cells assessed as cisplatin IC50 at 10 uM after 48 hrs by MTT assay (Rvb = 43.11 nM), IC50=0.04011μM | 30455148 |
| Lucena 1 | Function assay | 12.5 uM | 1 hr | Inhibition of P-gp-mediated Rho-123 efflux in human Lucena 1 cells at 12.5 uM preincubated for 1 hr followed by Rho-123 addition measured after 1 hr by flow cytometry | 30613324 |
| Lucena 1 | Function assay | 25 uM | 1 hr | Inhibition of P-gp-mediated Rho-123 efflux in human Lucena 1 cells at 25 uM preincubated for 1 hr followed by Rho-123 addition measured after 1 hr by flow cytometry | 30613324 |
| MCF7/ADR | Antiproliferative assay | 5 uM | 48 hrs | Potentiation of adriamycin-induced antiproliferative activity against human MCF7/ADR cells assessed as adriamycin IC50 at 5 uM measured after 48 hrs by MTT assay (Rvb = 89.14 +/- 4.89 uM), IC50=2.25μM | 30837097 |
| MCF7/Dox | Function assay | 12.5 uM | 48 hrs | Reversal of P-gp-mediated multidrug resistance in human MCF7/Dox cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 12.5 uM after 48 hrs by MTT assay (Rvb = 51.19 +/- 0.95 microM), IC50=10.1μM | 31325783 |
| KBtax | Function assay | 100 uM | 1 hr | Inhibition of P-gp efflux in human KBtax cells at 100 uM after 1 hr by flow cytometry | 31419740 |
| KBV | Function assay | 10 uM | 72 hrs | Reversal of P-gp-mediated multidrug resistance in human KBV cells assessed as potentiation of paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 10 uM after 72 hrs by MTT assay (Rvb = 352.31 +/- 10.9 nM), IC50=0.01843μM | 31505451 |
| KBV | Function assay | 10 uM | 72 hrs | Reversal of P-gp-mediated multidrug resistance in human KBV cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 10 uM after 72 hrs by MTT assay (Rvb = 2.92 +/- 0.31 nM), IC50=0.03502μM | 31505451 |
| KBV | Function assay | 10 uM | 72 hrs | Reversal of P-gp-mediated multidrug resistance in human KBV cells assessed as potentiation of irinotecan-induced cytotoxicity by measuring irinotecan IC50 at 10 uM after 72 hrs by MTT assay (Rvb = 49.2 +/- 0.46 nM), IC50=10.37μM | 31505451 |
| HepG2/Dox | Function assay | 10 uM | 4 hrs | Reversal of P-gp mediated drug efflux in human HepG2/Dox cells assessed as increase in intracellular doxorubicin accumulation at 10 uM preincubated for 4 hrs followed by doxorubicin addition measured after 1 hr incubation by fluorescence microscopic analy | 31585275 |
| HepG2/Dox | Function assay | 10 uM | 4 hrs | Reversal of P-gp mediated drug efflux in human HepG2/Dox cells assessed as increase in intracellular Rhodamine123 accumulation at 10 uM preincubated for 4 hrs followed by Rh123 addition measured after 1 hr incubation by fluorescence microscopic analysis | 31585275 |
| HepG2/Dox | Function assay | 5 to 10 uM | 4 hrs | Reversal of P-gp mediated drug efflux in human HepG2/Dox cells assessed as increase in intracellular doxorubicin accumulation at 5 to 10 uM preincubated for 4 hrs followed by doxorubicin addition measured after 1 hr incubation by flow cytometry analysis | 31585275 |
| HepG2/Dox | Function assay | 5 to 10 uM | 4 hrs | Reversal of P-gp mediated drug efflux in human HepG2/Dox cells assessed as increase in intracellular Rhodamine123 accumulation at 5 to 10 uM preincubated for 4 hrs followed by Rh123 addition measured after 1 hr incubation by flow cytometry analysis | 31585275 |
| MCF7/ADM | Function assay | 10 uM | 4 hrs | Reversal of P-gp mediated drug efflux in human MCF7/ADM cells assessed as increase in intracellular doxorubicin accumulation at 10 uM preincubated for 4 hrs followed by doxorubicin addition measured after 1 hr incubation by fluorescence microscopic analys | 31585275 |
| MCF7/ADM | Function assay | 10 uM | 4 hrs | Reversal of P-gp mediated drug efflux in human MCF7/ADM cells assessed as increase in intracellular Rhodamine123 accumulation at 10 uM preincubated for 4 hrs followed by Rh123 addition measured after 1 hr incubation by fluorescence microscopic analysis | 31585275 |
| HepG2/Dox | Function assay | 5 to 10 uM | 4 hrs | Inhibition of P-gp mediated doxorubicin efflux in human HepG2/Dox cells at 5 to 10 uM preincubated for 4 hrs followed by co-incubation with doxorubicin for 2 hrs followed by doxorubicin wash-out and measured after 120 mins incubation with drug containing | 31585275 |
| MCF7/ADM | Function assay | 5 to 10 uM | 4 hrs | Inhibition of P-gp mediated doxorubicin efflux in human MCF7/ADM cells at 5 to 10 uM preincubated for 4 hrs followed by co-incubation with doxorubicin for 2 hrs followed by doxorubicin wash-out and measured after 120 mins incubation with drug containing c | 31585275 |
| K562/ADR | Function assay | 10 to 20 uM | 30 mins | Inhibition of P-glycoprotein in human K562/ADR cells at 10 to 20 uM after 30 mins by rhodamine 123 staining-based fluorescence assay | ChEMBL |
| K562 | Function assay | 10 to 20 uM | 1 hr | Inhibition of P-glycoprotein in doxorubicin-resistant Homo sapiens (human) K562 cells overexpressing P-gp assessed as increase in intracellular Rh123 accumulation at 10 to 20 uM after 1 hr by flow cytometric analysis | ChEMBL |
| HCT116/VM46 cell | Function assay | 1 μM | Effect on vinblastine IC50 against MDR human carcinoma HCT116/VM46 cell line at a dose of 1 uM concentration, IC50=0.004 μM | 12729663 | |
| HCT15 | Function assay | 0.8 to 12.5 ug/mL | Modulation of P-gp in human HCT15 cells assessed as increase in DINIB-induced cytotoxicity at 0.8 to 12.5 ug/mL | 11754602 | |
| UO31 | Function assay | 0.8 to 12.5 ug/mL | Modulation of P-gp in human UO31 cells assessed as increase in DINIB-induced cytotoxicity at 0.8 to 12.5 ug/mL | 11754602 | |
| CAKI1 | Function assay | 0.8 to 12.5 ug/mL | Modulation of P-gp in human CAKI1 cells assessed as increase in DINIB-induced cytotoxicity at 0.8 to 12.5 ug/mL | 11754602 | |
| BHK21 | Cytotoxicity assay | 10 to 20 uM | Cytotoxicity against human MRP1 expressing hamster BHK21 cells at 10 to 20 uM by MTT assay | 17646169 | |
| Caco-2 | Function assay | 100 uM | Activation of human P-glycoprotein ATPase in Caco-2 cells assessed as ATP depletion at 100 uM | 18257545 | |
| PC12 | Autophagy assay | 1 uM | Induction of autophagy in differentiated rat stable inducible PC12 cells assessed as increase in LC3-2 level cell pretreated at 1 uM in presence of 400 nM bafilomycin A1 | 18391949 | |
| HCT15 | Function assay | 40 uM | Inhibition of MDR1 in human HCT15 cells assessed as calcein-AM efflux at 40 uM by fluorescence assay | 21348461 | |
| K562/A02 | Function assay | 10 uM | Reversal of p-glycoprotein-mediated multidrug-resistant in human K562/A02 cells assessed as increase of adriamycin-induced cytotoxic effect at 10 uM treated 24 hrs before adriamycin challenge followed by drug washout by MTS assay, IC50=12.92μM | 22405646 | |
| A549/CDDP | Function assay | 1.2 uM | Inhibition of P-gp in human A549/CDDP cells assessed as accumulation of rhodamine 123 at 1.2 uM by flow cytometry | 26891099 | |
| KBV | Function assay | 10 uM | Reversal of P-gp-mediated drug resistance in human KBV cells assessed as potentiation of paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 10 uM, IC50=0.0049μM | 30384042 | |
| HepG2/DOX | Function assay | 10 uM | Reversal of P-gp mediated multidrug resistance in human HepG2/DOX cells assessed as doxorubicin IC50 at 10 uM measured within 48 hrs by MTT assay (Rvb = 69.3 +/- 3.9 uM), IC50=1.3μM | 31585275 | |
| MCF7/ADM | Function assay | 10 uM | Reversal of P-gp mediated multidrug resistance in human MCF7/ADM cells assessed as doxorubicin IC50 at 10 uM measured within 48 hrs by MTT assay (Rvb = 151.7 +/- 5 uM), IC50=3.7μM | 31585275 | |
| HepG2/DOX | Function assay | 5 uM | Reversal of P-gp mediated multidrug resistance in human HepG2/DOX cells assessed as doxorubicin IC50 at 5 uM measured within 48 hrs by MTT assay (Rvb = 69.3 +/- 3.9 uM), IC50=4.7μM | 31585275 | |
| MCF7/ADM | Function assay | 5 uM | Reversal of P-gp mediated multidrug resistance in human MCF7/ADM cells assessed as doxorubicin IC50 at 5 uM measured within 48 hrs by MTT assay (Rvb = 151.7 +/- 5 uM), IC50=17.8μM | 31585275 | |
| KB31 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human KB31 cells after 48 hrs by SRB method, IC50=45.2μM | 10346948 | |
| KBV1 | Cytotoxicity assay | 48 hrs | Cytotoxicity against vinblastine resistant human KBV1 cells after 48 hrs by SRB method, IC50=39.2μM | 10346948 | |
| KBV1 | Cytotoxicity assay | 48 hrs | Cytotoxicity against vinblastine resistant human KBV1 cells after 48 hrs in presence of 100 nM vinblastine by SRB method, IC50=1.6μM | 10346948 | |
| KB/MDR | Function assay | 1 h | Concentration that causes 50% of maximum vinblastine accumulation in KB/MDR cells in 1 h, EC50=14μM | 15481991 | |
| Caco-2 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human Caco-2 cells assessed as cell viability by MTT assay after 48 hrs, IC10=24.9μM | 17276076 | |
| CEM/VLB500 | Function assay | 3 days | Reversal of P-gp-mediated multidrug resistance to vinblastine in human CEM/VLB500 cells after 3 days by resazurin assay, EC50=1.041μM | 17399990 | |
| A2780 | Function assay | 30 mins | Inhibition of human Pgp in A2780 cells after 30 mins by calcein AM assay, IC50=4.57088μM | 18083034 | |
| A2780 | Function assay | 30 mins | Inhibition of human Pgp in A2780 cells after 30 mins by Hoechst 33342 assay, IC50=6.60693μM | 18083034 | |
| MDCK2 | Function assay | 20 mins | Enhancement of calcein-AM uptake in MDCK2 cells over expressing MDR1 after 20 mins, EC50=5.1μM | 18849167 | |
| MDCK2 | Function assay | 20 mins | Inhibition of human MDR1 expressed in MDCK2 cells assessed as enhancement of Calcein-AM uptake treated 30 mins before Calcein-AM challenge measured after 20 mins, IC50=14μM | 19402665 | |
| 2008/MRP1 | Function assay | 120 mins | Reversal of MRP1-mediated doxorubicin resistance in doxorubicin co-incubated human 2008/MRP1 cells assessed as minimum concentration required for restoration of doxorubicin accumulation after 120 mins by spectrofluorimetry relative to accumulation in huma | 19725578 | |
| BHK21 | Cytotoxicity assay | 96 hrs | Cytotoxicity against hamster BHK21 cells expressing MRP1 after 96 hrs by MTT assay, IC50=10.6μM | 20691599 | |
| MDCK | Function assay | 30 mins | Inhibition of human MDR1 expressed in MDCK cells assessed as calcein AM accumulation after 30 mins by fluorescence assay, IC50=0.5μM | 22112208 | |
| MDCK | Function assay | 30 mins | Inhibition of MRP1 expressed in MDCK cells assessed as calcein AM accumulation after 30 mins by fluorescence assay, IC50=6.8μM | 22112208 | |
| LCC6MDR | Function assay | 5 days | Reversal of P-gp-mediated doxorubicin-resistance in human LCC6MDR cells after 5 days by MTS assay, EC50=0.245μM | 22320402 | |
| LCC6MDR | Function assay | 5 days | Reversal of P-gp-mediated vincristine-resistance in human LCC6MDR cells after 5 days by MTS assay, EC50=0.385μM | 22320402 | |
| LCC6MDR | Function assay | 5 days | Reversal of P-gp-mediated paclitaxel-resistance in human LCC6MDR cells after 5 days by MTS assay, EC50=0.428μM | 22320402 | |
| LCC6MDR | Function assay | 5 days | Reversal of P-gp-mediated vinblastin-resistance in human LCC6MDR cells after 5 days by MTS assay, EC50=0.503μM | 22320402 | |
| MDA435/LCC6MDR | Function assay | 150 mins | Inhibition of P-gp overexpressed in human MDA435/LCC6MDR cells assessed as accumulation of doxorubicin after 150 mins by fluorescence spectrophotometric analysis, MIC=8μM | 22320402 | |
| CCRF-CEM/VCR1000 | Function assay | 240 secs | Inhibition of P-glycoprotein-mediated daunorubicin efflux from human CCRF-CEM/VCR1000 cells after 240 secs by FACS flow cytometric analysis, IC50=0.57544μM | 22452412 | |
| BHK | Function assay | 30 mins | Induction of ATPase activity of human His10-tagged P-gp expressed in BHK cells assessed as inorganic phosphate release after 30 mins by Michaelis-Menten analysis, Km=24μM | 22533905 | |
| C1-6-37-3 | Function assay | 30 mins | Inhibition of human voltage-dependent L-type calcium channel subunit alpha1C/alpha2delta/beta2a expressed in C1-6-37-3 cells assessed as inhibition of K+-induced calcium influx incubated for 30 mins prior to K+-induction by Fluo-4-AM based FLIPR assay, IC50=0.9μM | 22694270 | |
| KB/VCR | Function assay | 72 hrs | Inhibition of p-gp in human KB/VCR cells assessed as potentiation of 100 nM docetaxel-induced cytotoxicity after 72 hrs by MTT assay, EC50=1.253μM | 23683834 | |
| MDCK | Function assay | 30 mins | Inhibition of P-glycoprotein (unknown origin) expressed in MDCK cells assessed as reduction of calcein-AM transport after 30 mins by fluorescence assay, EC50=20μM | 24607999 | |
| NCI/ADR-RES | Function assay | 20 mins | Inhibition of human P-glycoprotein expressed in NCI/ADR-RES cells assessed as reduction of calcein-AM transport after 20 mins by fluorescence assay | 24992153 | |
| MDCK | Function assay | 30 mins | Inhibition of MRP1 (unknown origin) expressed in MDCK cells after 30 mins by Calcein-AM assay, IC50=3.5μM | 25093931 | |
| A7R5 | Function assay | 15 mins | Antagonist activity at calcium channel in rat A7R5 cells assessed as inhibition of Cacl2/KCl-induced increase in intracellular Ca2+ incubated for 15 mins prior to Cacl2/KCl challenge by fluorescence assay, IC50=0.3μM | 25311564 | |
| MES-SA | Function assay | 15 mins | Modulation of P-gp mediated drug efflux in human MES-SA cells assessed as accumulation of rhodamine-123 incubated for 15 mins prior to rhodamine-123 addition measured after 1 hr by fluorescence analysis, EC50=7.1μM | 25311564 | |
| H69 | Function assay | 15 mins | Modulation of MRP1 mediated drug efflux in doxorubicin-resistant human H69 cells assessed as accumulation of calcein AM incubated for 15 mins prior to calcein AM addition measured after 30 mins by fluorescence analysis, EC50=27.8μM | 25311564 | |
| MES-SA | Function assay | 15 mins | Modulation of BCRP1 mediated drug efflux in mitoxantrone-resistant human MES-SA cells assessed as accumulation of hoechst 33342 incubated for 15 mins prior to rhodamine-123 addition measured after 90 mins by fluorescence analysis, EC50=37.3μM | 25311564 | |
| MDA435/LCC6MDR | Function assay | 5 days | Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversing doxorubicin resistance measured as cell survival after 5 days by MTS assay, EC50=0.245μM | 25985195 | |
| MDA435/LCC6MDR | Function assay | 5 days | Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversing vincristine resistance measured as cell survival after 5 days by MTS assay, EC50=0.385μM | 25985195 | |
| MDA435/LCC6MDR | Function assay | 5 days | Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversing paclitaxel resistance measured as cell survival after 5 days by MTS assay, EC50=0.446μM | 25985195 | |
| MDA435/LCC6MDR | Function assay | 5 days | Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversing vinblastine resistance measured as cell survival after 5 days by MTS assay, EC50=0.503μM | 25985195 | |
| KB/VJ300 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human KB/VJ300 cells assessed as cell viability after 72 hrs by MTT assay in presence of 0.121 uM vincristine, IC50=10.3μM | 26717050 | |
| KB/VJ300 | Growth inhibition assay | 72 hrs | Growth inhibition of human KB/VJ300 cells after 72 hrs in presence of vincristine by MTT assay, IC50=4.6μM | 26918761 | |
| L5178Y | Cytotoxicity assay | 72 hrs | Cytotoxicity against multi-drug resistant mouse L5178Y cells assessed as growth inhibition after 72 hrs by MTT assay, IC50=47.85μM | 27156771 | |
| HLF | Cytotoxicity assay | 48 hrs | Cytotoxicity against HLF cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay, IC50=27.18μM | 27328029 | |
| MDA435/LCC6MDR | Function assay | 5 days | Inhibition of P-gp in human MDA435/LCC6MDR cells assessed as reduction of doxorubicin cytotoxic IC50 by half after 5 days by Cell Titer 96 Aqueous assay, EC50=0.245μM | 27750197 | |
| MDA435/LCC6MDR | Function assay | 150 mins | Inhibition of P-gp in human MDA435/LCC6MDR cells assessed as increase in doxorubicin accumulation to half of parental LCC6 cells measured after 150 mins by fluorescence spectrophotometric method, EC50=0.35μM | 27750197 | |
| MDA435/LCC6MDR | Function assay | 5 days | Inhibition of P-gp in human MDA435/LCC6MDR cells assessed as reduction of vincristine cytotoxic IC50 by half measured after 5 days by Cell Titer 96 Aqueous assay, EC50=0.385μM | 27750197 | |
| MDA435/LCC6MDR | Function assay | 5 days | Inhibition of P-gp in human MDA435/LCC6MDR cells assessed as reduction of paclitaxel cytotoxic IC50 by half measured after 5 days by Cell Titer 96 Aqueous assay, EC50=0.446μM | 27750197 | |
| MDA435/LCC6MDR | Function assay | 5 days | Inhibition of P-gp in human MDA435/LCC6MDR cells assessed as reduction of vinblastine cytotoxic IC50 by half measured after 5 days by Cell Titer 96 Aqueous assay, EC50=0.503μM | 27750197 | |
| MES-SA/Dx5 | Function assay | 72 hrs | Inhibition of P-gp in human MES-SA/Dx5 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring compound concentration required for reduction of doxorubicin IC50 by half after 72 hrs by MTT assay, EC50=0.7μM | 28043777 | |
| MES-SA/Dx5 | Function assay | 72 hrs | Inhibition of P-gp in human MES-SA/Dx5 cells assessed as potentiation of paclitaxel-induced cytotoxicity by measuring compound concentration required for reduction of paclitaxel IC50 by half after 72 hrs by MTT assay, EC50=0.8μM | 28043777 | |
| MES-SA/Dx5 | Function assay | 72 hrs | Inhibition of P-gp in human MES-SA/Dx5 cells assessed as potentiation of actinomycin D-induced cytotoxicity by measuring compound concentration required for reduction of actinomycin D IC50 by half after 72 hrs by MTT assay, EC50=0.9μM | 28043777 | |
| MES-SA/Dx5 | Function assay | 72 hrs | Inhibition of P-gp in human MES-SA/Dx5 cells assessed as potentiation of vinblastine-induced cytotoxicity by measuring compound concentration required for reduction of vinblastine IC50 by half after 72 hrs by MTT assay, EC50=1μM | 28043777 | |
| K562/DOX | Function assay | 30 mins | Inhibition of P-gp in human K562/DOX cells assessed as drug level causing 50% increase in nuclear pirarubicin concentration incubated for 30 mins by spectroflurometry, I0.5=1.6μM | 28113128 | |
| K562/A02 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human K562/A02 cells overexpressing P-gp after 48 hrs by MTT assay, IC50=31.28μM | 28301155 | |
| K562 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human K562 cells after 48 hrs by MTT assay, IC50=36.7μM | 28301155 | |
| K562/A02 | Function assay | 48 hrs | Inhibition of ABCB1 in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring ADR IC50 measured after 48 hrs by MTT assay (Rvb = 51.34 +/- 5.1 uM), IC50=10.73μM | 28645831 | |
| K562/A02 | Function assay | 48 hrs | Inhibition of ABCB1 in human K562/A02 cells assessed as potentiation of adriamycin-induced cytotoxicity by measuring ADR IC50 treated for 48 hrs followed by compound washout measured immediately by MTT assay (Rvb = 51.34 +/- 5.1 uM), IC50=31.28μM | 28645831 | |
| MCF7/ADR | Function assay | 48 hrs | Inhibition of P-gp in human MCF7/ADR cells assessed as potentiation of doxorubicin-induced cytotoxicity after 48 hrs by MTT assay, EC50=0.2451μM | 29407947 | |
| MCF7/ADR | Function assay | 150 mins | Competitive inhibition of P-gp in human MCF7/ADR cells after 150 mins in presence of doxorubicin by Lineweaver-Burk plot analysis, Ki=2.88μM | 29407947 | |
| MCF7/ADR | Function assay | 150 mins | Competitive inhibition of P-gp in human MCF7/ADR cells after 150 mins in presence of doxorubicin by Dixon plot analysis, Ki=2.92μM | 29407947 | |
| MCF7/ADR | Function assay | 150 mins | Inhibition of P-gp in human MCF7/ADR cells assessed as concentration required to restore doxorubicin accumulation in cells after 150 mins by fluorescence assay relative to MCF7 cells, Activity=40μM | 29407947 | |
| MCF7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay, IC50=48.91μM | 29407947 | |
| MCF7/ADR | Function assay | 48 hrs | Inhibition of P-gp in human MCF7/ADR cells assessed as cell viability after 48 hrs by MTT assay, EC50=20.54μM | 29656198 | |
| KB/VJ300 | Growth inhibition assay | 72 hrs | Growth inhibition of human KB/VJ300 cells after 72 hrs in presence of 0.1 uM of vincristine by MTT assay, IC50=0.1μM | 29746134 | |
| SW620/AD300 | Function assay | 2 hrs | Inhibition of ABCB1 in human SW620/AD300 cells assessed as intracellular accumulation of paclitaxel up to 2 uM treated at 2 hrs post paclitaxel treatment for 30 mins in paclitaxel free medium by HPLC analysis | 29975529 | |
| SW620/AD300 | Function assay | 4 hrs | Inhibition of ABCB1 in human SW620/AD300 cells assessed as decrease in rhodamine 123 efflux up to 2 uM preincubated for 4 hrs followed by 30 mins incubation in Rho-123 containing medium and subsequent incubation in Rho-123 free medium up to 120 mins by fl | 29975529 | |
| SW620/AD300 | Function assay | 4 hrs | Inhibition of ABCB1 in human SW620/AD300 cells assessed as intracellular accumulation of [3H]-paclitaxel up to 2 uM preincubated for 4 hrs followed by [3H]-paclitaxel addition measured after 2 hrs by liquid scintillation counting method | 29975529 | |
| 2008/MRP1 | Function assay | 5 days | Inhibition of MRP1 in human 2008/MRP1 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring reduction in cell survival after 5 days by MTS assay, EC50=1.925μM | 30351934 | |
| MDCK | Function assay | 30 mins | Inhibition of MDR1 (unknown origin) expressed in MDCK cells assessed as reduction in calcein-AM efflux preincubated for 30 mins followed by calcein-AM addition measured after 30 mins by spectrofluorimetric method, IC50=1.3μM | 30384046 | |
| MDCK | Function assay | 30 mins | Inhibition of MRP1 (unknown origin) expressed in MDCK cells assessed as reduction in calcein-AM efflux preincubated for 30 mins followed by calcein-AM addition measured after 30 mins by spectrofluorimetric method, IC50=4.5μM | 30384046 | |
| MCF7/ADR | Function assay | 48 hrs | Inhibition of P-gp in doxorubicin-resistant human MCF7/ADR cells assessed as reversal of doxorubicin resistance by measuring doxorubicin IC50 incubated for 48 hrs by MTT assay (Rvb = doxorubicin alone = 64.8 +/- 2.1 uM), IC50=4.7μM | 30860373 | |
| KB/VJ300 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human KB/VJ300 cells after 72 hrs in presence of vincristine by MTT assay, IC50=0.8μM | 30869890 | |
| MDCK-MDR1 | Function assay | 30 mins | Inhibition of P-gp (unknown origin) expressed in MDCK-MDR1 cells assessed as increase in calcein-AM accumulation incubated for 30 mins by calcein-AM dye based fluorescence assay, EC50=0.5μM | 31494468 | |
| MDCK | Function assay | 30 mins | Inhibition of BCRP (unknown origin) expressed in MDCK cells assessed as increase in Hoechst 33342 accumulation incubated for 30 mins by Hoechst 33342 dye based fluorescence assay, EC50=0.9μM | 31494468 | |
| K562/DOX | Function assay | 30 mins | Inhibition of P-gp in human K562/DOX cells assessed as drug level causing 50% increase in nuclear pirarubicin concentration incubated for 30 mins by fluorescence based assay, I0.5=1.6μM | 31494468 | |
| MDCK | Function assay | 30 mins | Inhibition of MRP1 (unknown origin) expressed in MDCK cells assessed as increase in calcein-AM accumulation incubated for 30 mins by calcein-AM dye based fluorescence assay, EC50=6.8μM | 31494468 | |
| KB/VJ300 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human vincristine-rsistant KB/VJ300 cells assessed as reduction in cell growth after 72 hrs by MTT assay, IC50=0.4μM | 31642315 | |
| HeLa | Function assay | 30 mins | Inhibition of P-glycoprotein 1 in human HeLa cells assessed as intracellular accumulation of Hoechst 33342 dye after 30 mins by fluorescence microscopic analysis, IC50=1.7μM | ChEMBL | |
| HEK293 | Function assay | 24 hrs | Inhibition of Marburg virus envelope glycoprotein-mediated cell entry in rVSIV-deltaG-MarV-GP pseuotype virus infected HEK293 cells after 24 hrs post transfection by luciferase reporter gene assay, IC50=13μM | ChEMBL | |
| NIH-3T3-G185 | Function assay | TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells, IC50=6.5μM | 11716514 | ||
| NIH-3T3-G185 | Function assay | TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells, IC50=4.7μM | 11716514 | ||
| NIH-3T3-G185 | Function assay | TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells, IC50=4.2μM | 11716514 | ||
| G185 | Function assay | TP_TRANSPORTER: inhibition of Daunorubicin efflux (Daunorubicin: ? uM) in G185 cells, IC50=4.2μM | 11454724 | ||
| Caco-2 | Function assay | TP_TRANSPORTER: inhibition of Taxol transepithelial transport (basal to apical) in Caco-2 cells, Ki=3μM | 11405287 | ||
| Caco-2 | Function assay | TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM) in Caco-2 cells, IC50=2.1μM | 10820137 | ||
| P388 | Function assay | Multidrug-resistant reversal activity using P388/VMDRC.04 cells (a subline of P388 murine leukemia cells expressing human recombinant human P-glycoprotein) in the presence of 10 nM vincristine, IC50=3.1μM | 10386932 | ||
| S1-B1-20 | Function assay | In vitro concentration required to inhibit tumor activity on subclone of human colon carcinoma cells (S1-B1-20) resistant to bisantrene, IC50=17.27μM | 10377220 | ||
| K562/DOX MDR | Cytotoxicity assay | Ability to potentiate DOX cytotoxicity on K562/DOX MDR cells. Cell survival was assayed by MTT conversion, IC50=37μM | 9986718 | ||
| HeLa | Function assay | TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing HeLa cells, Ki=2.9μM | 9655880 | ||
| B16/F10 | Function assay | Inhibition of human MDR1 expressed in mouse B16/F10 cells assessed as increase in doxorubicin accumulation by fluorimetry, ED50=3μM | 9461658 | ||
| MCF/ADR | Function assay | Reversal of P-gp-mediated multidrug resistance in human MCF/ADR cells assessed as increase in rhodamine 6G accumulation | 8984151 | ||
| CCRF-CEM | Function assay | The effective dose was measured against P-glycoprotein expressing CCRF-CEM cells in the presence of 5 uM etoposide, ED50=3.4μM | 7629817 | ||
| CCRF-CEM | Function assay | The effective dose was measured against P-glycoprotein expressing CCRF-CEM cells in the presence of 5 uM daunomycin, ED50=0.045μM | 7629817 | ||
| NG108-15 | Function assay | The compound was tested for inhibition of calcium influx into neuronal (NG108-15) cells, IC50=6.5μM | 2033584 | ||
| NIH-3T3-G185 | Function assay | TP_TRANSPORTER: inhibition of Calcein-AM efflux in NIH-3T3-G185 cells, IC50=28.9μM | 11716514 | ||
| NIH-3T3-G185 | Function assay | TP_TRANSPORTER: inhibition of Tetramethylrosamine efflux in NIH-3T3-G185 cells, IC50=38.2μM | 11716514 | ||
| NIH-3T3-G185 | Function assay | TP_TRANSPORTER: inhibition of JC-1 efflux in NIH-3T3-G185 cells, IC50=42μM | 11716514 | ||
| MDA-435/LCC6 and MDA-435/LCC6-MDRI cells | Function assay | Concentration that reduces difference in reversal of [3H]VBL accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells by 50%, EC50=1.2μM | 11784143 | ||
| MDA-435/LCC6 and MDA-435/LCC6-MDRI cells | Function assay | Concentration that reduces the difference in reversal of DOX accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells by 50%., EC50=2.4μM | 11784143 | ||
| MDA-435/LCC6 | Function assay | Effect on reversal of [3H]- VBL accumulation in MDA-435/LCC6 (Pgp-negative) cells., EC50=3.1μM | 11784143 | ||
| MDA435/LCC6 MDR1 | Function assay | TP_TRANSPORTER: reversal of Vinblastine accumulation (Vinblastine: 0.005 uM) in MDA435/LCC6 MDR1 cells, EC50=3.1μM | 11784143 | ||
| MDA-435/LCC6 | Function assay | Effect on reversal of DOX accumulation in MDA-435/LCC6 (Pgp-negative) cells., EC50=4.1μM | 11784143 | ||
| BTI-TN5B1-4 | Function assay | TP_TRANSPORTER: ATP hydrolysis in membrane fraction from High Five (BTI-TN5B1-4) cells, Km=4.06μM | 11785684 | ||
| MDCK | Function assay | TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) in MDR1-expressing MDCK cells, Ki=15.1μM | 12134945 | ||
| human embryonic kidney cells | Function assay | K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1, IC50=0.143μM | 12190308 | ||
| HCT15/CL02 | Function assay | TP_TRANSPORTER: drug resistance (paclitaxel) in HCT15/CL02 cells, IC50=2.21μM | 12569305 | ||
| MES-SA/DX5 | Function assay | TP_TRANSPORTER: drug resistance (paclitaxel) in MES-SA/DX5 cells, IC50=4.78μM | 12569305 | ||
| Caco-2 | Function assay | TP_TRANSPORTER: transepithelial transport of digoxin (basal to apical) in Caco-2 cells, Ki=0.88μM | 12636153 | ||
| L-MDR1 | Function assay | TP_TRANSPORTER: cell accumulation of calcein in L-MDR1 cells, IC50=18.9μM | 12649369 | ||
| LLC-PK1 | Function assay | Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay, IC50=2μM | 12699389 | ||
| LLC-PK1 | Function assay | TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells, IC50=2μM | 12699389 | ||
| LLC-PK1 | Function assay | Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay, IC50=6.3μM | 12699389 | ||
| LLC-PK1 | Function assay | TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells, IC50=6.3μM | 12699389 | ||
| LLC-PK1 | Function assay | Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay, IC50=10μM | 12699389 | ||
| LLC-PK1 | Function assay | TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells, IC50=10μM | 12699389 | ||
| CHO | Function assay | Inhibition of K+ channel activity in CHO cells expressing HERG Kv11.1, IC50=0.143μM | 12729675 | ||
| mammalian cells | Function assay | Inhibition of human Potassium channel HERG expressed in mammalian cells, IC50=0.14125μM | 12873512 | ||
| AML-2/D100 | Function assay | TP_TRANSPORTER: drug resistance (vincristine) in AML-2/D100 cells, IC50=0.4μM | 15240100 | ||
| Caco-2 | Function assay | TP_TRANSPORTER: transepithelial transport of fexofenadine in Caco-2 cells, IC50=8.44μM | 15359574 | ||
| Sf9 | Function assay | Michaelis-Menten constant for human P-glycoprotein expressed in Sf9 cells, Km=2μM | 15863325 | ||
| K562 | Function assay | Reversal of P-gp-mediated multidrug resistance in doxorubicin-resistant human K562 cells assessed as drug concentration causing half-maximal increase in nuclear pirarubicin concentration, Activity=1.6μM | 16279802 | ||
| Caco-2 | Function assay | Inhibition of Pgp measured as inhibition of [3H]vinblastine basolateral to apical transport in Caco-2 cells, EC50=20μM | 17064079 | ||
| MDA435/LCC6 | Function assay | Reversal of vinblastine resistance in multidrug resistant MDA435/LCC6 cells by MTS assay, IC50=0.00025μM | 17154505 | ||
| MDA435/LCC6 | Function assay | Reversal of paclitaxel resistance in multidrug resistant MDA435/LCC6 cells by MTS assay, IC50=0.0052μM | 17154505 | ||
| MDA435/LCC6 | Function assay | Reversal of paclitaxel resistance in multidrug resistant MDA435/LCC6 cells by MTS assay, EC50=0.7μM | 17154505 | ||
| K562 | Function assay | Inhibition of human Pgp in anthracycline-resistant K562 cells assessed as drug level causing half maximal increase in nuclear concentration of pirarubicin, Activity=1.6μM | 17256837 | ||
| A549 | Function assay | Inhibition of P-gp in A549 cells assessed as drug concentration required to double baseline fluorescence level by calcein-AM uptake assay, Activity=7μM | 17419606 | ||
| THP1 | Antileishmanial assay | Antileishmanial activity against wild-type Leishmania amazonensis MHOM/BR/1973/MM2269 promastigotes infected in human THP1 cells by luciferase based assay, IC50=19.1μM | 17452480 | ||
| THP1 | Antileishmanial assay | Antileishmanial activity against wild-type Leishmania major LV39 promastigotes infected in human THP1 cells by luciferase based assay, IC50=40.3μM | 17452480 | ||
| THP1 | Antileishmanial assay | Antileishmanial activity against wild-type Leishmania infantum MHOM/MA/67/ITMAP-263 promastigotes infected in human THP1 cells by luciferase based assay, IC50=43.2μM | 17452480 | ||
| BHK21 | Function assay | Inhibition of human MRP1 mediated LTC4 transport in hamster BHK21 cells in presence of glutathione by rapid filtration technique | 17646169 | ||
| A2780/ADR | Function assay | Inhibition of P-glycoprotein expressed in A2780/ADR cells by calcein AM assay, IC50=4.57088μM | 17890094 | ||
| Caco-2 | Function assay | Inhibition of human Pgp mediated [3H]vinblastine transport in human Caco-2 cells, EC50=20μM | 17936633 | ||
| Caco-2 | Function assay | Inhibition of human P-glycoprotein mediated [3H]vinblastine transport in human Caco-2 cells, EC50=20μM | 18257545 | ||
| Caco-2 | Function assay | Inhibition of human P-gp mediated [3H]vinblastine transport activity in human Caco-2 cells, EC50=20μM | 18276145 | ||
| KBV20C | Cytotoxicity assay | Cytotoxicity against multidrug resistant P-gp expressing human KBV20C cells assessed as cell viability in presence of paclitaxel by MTS assay, IC50=0.01μM | 18295490 | ||
| KBV20C | Cytotoxicity assay | Cytotoxicity against multidrug resistant P-gp expressing human KBV20C cells assessed as cell viability in presence of vincristine by MTS assay, IC50=0.2μM | 18295490 | ||
| KBV20C | Function assay | Inhibition of Pgp in multidrug resistant human KBV20C cells assessed as increase in intracellular accumulation of Rh123 | 18295490 | ||
| K562 | Function assay | Activity of Pgp-ATPase in doxorubicin-resistant human K562 cells, Km=0.7μM | 18313307 | ||
| K562 | Function assay | Inhibition of Verapamil-stimulated human Pgp-ATPase activity in doxorubicin-resistant K562 cells, Km=0.89μM | 18313307 | ||
| K562 | Function assay | Inhibition of Verapamil-stimulated human Pgp-ATPase activity in doxorubicin-resistant K562 cells, Vmax=22.39μM | 18313307 | ||
| K562 | Function assay | Activity of Pgp-ATPase in doxorubicin-resistant human K562 cells, Vmax=36.93μM | 18313307 | ||
| CHO | Function assay | Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique, IC50=0.14125μM | 18448342 | ||
| Caco-2 | Function assay | Inhibition of P-glycoprotein-mediated [3H]vinblastine transport in human Caco-2 cells, EC50=20μM | 18524592 | ||
| A2780 | Function assay | Inhibition of P-gp in human adriamycin-resistant A2780 cells by Hoechst 33342 assay, IC50=4.57088μM | 18678495 | ||
| A2780 | Function assay | Inhibition of P-gp in human A2780 cells, IC50=5.42μM | 18707884 | ||
| 2008 | Function assay | Inhibition of human MRP1 in human 2008 cells, IC50=9.66μM | 18707884 | ||
| HEK293 | Function assay | Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy, IC50=6.8μM | 18788725 | ||
| MCF7 | Function assay | Inhibition of human ERG in MCF7 cells, IC50=0.14454μM | 19110341 | ||
| K562 | Function assay | Reversal of P-glycoprotein-mediated multidrug resistance in human doxorubicin-resistant K562 cells assessed as drug level causing maximum increase in nuclear concentration of pirarubicin by spectrofluorimetry relative to control, Alpha max=0.7μM | 19140665 | ||
| K562 | Function assay | Reversal of P-glycoprotein-mediated multidrug resistance in human doxorubicin-resistant K562 cells assessed as drug level causing 50% increase in nuclear concentration of pirarubicin by spectrofluorimetry, Activity=1.6μM | 19140665 | ||
| smooth skeletal cells | Function assay | Displacement of (-)-[3H]devapamil from L-type calcium channel in rabbit smooth skeletal cells relative to verapamil, IC50=0.0602μM | 19203272 | ||
| A2780/ADR | Function assay | Inhibition of P-glycoprotein-mediated multidrug resistance in adriamycin-resistant human A2780/ADR cells by calcein AM assay, IC50=5.2μM | 19250834 | ||
| BHK | Function assay | Induction of human histidine10-tagged MDR1 ATPase activity expressed in BHK cells by apparent Michaelis-Menten constant, Km=24μM | 19402665 | ||
| 2008/MRP1 | Function assay | Reversal of MRP1-mediated doxorubicin-resistance in human 2008/MRP1 cells assessed as reduction of doxorubicin IC50 percent by half, Activity=2.6μM | 19725578 | ||
| 2008/MRP1 | Function assay | Inhibition of MRP1 in human 2008/MRP1 cells by Lineweaver-Burke plot analysis, Ki=13.2μM | 19725578 | ||
| 2008/MRP1 | Function assay | Inhibition of MRP1 in human 2008/MRP1 cells by dixon plot analysis, Ki=13.4μM | 19725578 | ||
| K562 | Function assay | Inhibition of P-glycoprotein-mediated multidrug resistance in human doxorubicin-resistant K562 cells assessed as drug level causing 50% increase in nuclear concentration of pirarubicin by spectrofluorimetry, INH=1.6μM | 20104851 | ||
| K562 | Function assay | Inhibition of Pgp-mediated multidrug resistance in doxorubicin-resistant human K562 cells assessed as drug level required for maximum increase in nuclear concentration of pirarubicin by fluorescence assay, Alpha max=0.7μM | 21145739 | ||
| K562 | Function assay | Inhibition of Pgp-mediated multidrug resistance in doxorubicin-resistant human K562 cells assessed as drug level required for 50% increase in nuclear concentration of pirarubicin by fluorescence assay, IC50=1.6μM | 21145739 | ||
| HEK-293 | Function assay | Inhibition of sodium current measured using whole-cell patch clamp experiments in HEK-293 cells stably transfected with hNaV1.5 cDNA, IC50=41.5μM | 21300721 | ||
| HCT15 | Function assay | Inhibition of ABC transporter in human HCT15 cells assessed as calcein-AM efflux up to 100 uM | 21348461 | ||
| HCT15 | Cytotoxicity assay | Cytotoxicity against MDR1 expressing human HCT15 cells | 21348461 | ||
| A2780adr | Function assay | Inhibition of P-gp expressed in A2780adr cells by calcein AM accumulation assay, IC50=5.4μM | 21354800 | ||
| MDCK | Function assay | Inhibition of MDR1 expressed in MDCK cells using rhodamine 123 staining by flow cytometry, IC50=9.8μM | 21354800 | ||
| MDA435/LCC6MDR | Function assay | Competitive inhibition of P-gp overexpressed in human MDA435/LCC6MDR cells assessed as accumulation of doxorubicin by Lineweaver-Burk plot analysis, Ki=1.75μM | 22320402 | ||
| MDA435/LCC6MDR | Function assay | Competitive inhibition of P-gp overexpressed in human MDA435/LCC6MDR cells assessed as accumulation of doxorubicin by Dixon plot analysis, Ki=1.75μM | 22320402 | ||
| HEK293 | Function assay | Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using estradiol-17beta-glucuronide substrate, IC50=32μM | 22587986 | ||
| BHK | Function assay | Binding affinity to human His10-tagged P-gp expressed in BHK cells assessed as induction of ATPase activity measured as inorganic phosphate release by spectrophotometric analysis, Km=24μM | 22727780 | ||
| ovary cells | Function assay | Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in Chinese hamster ovary cells heterologically expressing alpha-1C subunit, IC50=23.5μM | 22761000 | ||
| embryonic kidney cells | Function assay | Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit, IC50=24μM | 22761000 | ||
| embryonic kidney cells | Function assay | Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit, IC50=47μM | 22761000 | ||
| L929 | Function assay | Inhibition of Kv1.3 expressed in mouse L929 cells exposed to depolarizing step pulses from -80 mV to +40 mV by whole cell patch clamp method, IC50=8μM | 23084278 | ||
| K562 | Function assay | Inhibition of P-glycoprotein in human doxorubicin-resistant K562 cells assessed as half maximal increase of pirarubicin accumulation by spectrofluorometric analysis, IC50=1.6μM | 23245571 | ||
| CHO | Function assay | Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits, IC50=0.2μM | 23812503 | ||
| MDA435/LCC6MDR | Function assay | Modulation of p-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversal of paclitaxel resistance, EC50=0.4457μM | 24171478 | ||
| K562/DOX | Function assay | Modulatory activity at P-gp in human K562/DOX cells assessed as increase in nuclear concentration of pirarubicin by spectrofluorometric assay, IC50=1.6μM | 25282263 | ||
| MDA435/LCC6MDR | Function assay | Modulation of P-gp in human MDA435/LCC6MDR cells assessed as reversal of paclitaxel resistance, EC50=0.446μM | 26233798 | ||
| NIH/3T3 | Cytotoxicity assay | Intrinsic cytotoxicity against mouse NIH/3T3 cells by MTT assay, CC50=27μM | 26836364 | ||
| CHO | Function assay | Inhibition of human ERG expressed in CHO cells at holding potential of -90 mV by patch clamp method, IC50=0.53μM | 28797771 | ||
| K562/Dox | Function assay | Inhibition of P-gp in human K562/Dox cells assessed as increase in nuclear accumulation of pirarubicin by spectrofluorometric assay, IC50=1.6μM | 29162309 | ||
| K562/Dox | Function assay | Inhibition of P-gp in human K562/Dox cells assessed as compound concentration causing 50% increase in nuclear accumulation of pirarubicin by spectrofluorometric method, Activity=1.6μM | 29421572 | ||
| 12D7-MDR | Function assay | Inhibition of P-gp in human 12D7-MDR cells using calcein-AM as substrate, IC50=1.2μM | 31505928 | ||
| CHO | Cytotoxicity assay | Cytotoxicity against CHO cells by MTT assay, IC50=0.56μM | ChEMBL | ||
| CHRC5 | Function assay | Tested for in vitro proliferation and viability of multidrug resistant CHRC5 Chinese hamster cells in the presence and absence of doxorubicin in a modified MTT assay, EC50=1.2μM | ChEMBL | ||
| 点击查看更多细胞系数据 | |||||
生物活性
| 产品描述 | Verapamil HCl是L-型钙通道抑制剂，是第四类抗心律失常的药剂。Verapamil 可抑制 permeability-glycoprotein (P-gp) 和 CYP3A4。 | |
|---|---|---|
| 靶点 |
|
| 体外研究(In Vitro) | ||||
| 体外研究活性 | 重组CES2的水解酶活性基本上被diltiazem和verapamil抑制(Ki分别为0.25 ± 0.02、3.84 ± 0.99μM)。 |
|||
|---|---|---|---|---|
| 体内研究(In Vivo) | ||
| 体内研究活性 | Verapamil通过抑制钙离子内流而具有抗心律失常作用，抑制大鼠心脏氧的消耗，并且同时保存Cx43蛋白。 |
|
|---|---|---|
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05618132 | Recruiting | Angina Pectoris Variant|Angina Pectoris; Spasm-Induced|Angina Pectoris With Normal Coronary Arteriogram |
University Hospital Antwerp |
January 9 2023 | Not Applicable |
| NCT04406259 | Recruiting | Cluster Headache |
Centre Hospitalier Universitaire de Nice |
November 2 2020 | Phase 4 |
| NCT04014634 | Completed | Cluster Headache Episodic|Greater Occipital Nerve Injection |
Leiden University Medical Center|Netherlands Brain Foundation|Innovatiefonds Zorgverzekeraars |
August 1 2019 | Phase 4 |
化学信息&溶解度
| 分子量 | 491.06 | 分子式 | C27H38N2O4.HCl |
| CAS号 | 152-11-4 | SDF | Download Verapamil HCl SDF |
| Smiles | CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC.Cl | ||
| 储存条件(自收到货起) | |||
|
体外溶解度 |
DMSO : 98 mg/mL ( (199.56 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO) Water : 98 mg/mL (199.56 mM) Ethanol : 98 mg/mL (199.56 mM) |
摩尔浓度计算器 |
|
体内溶解度 现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂 |
动物体内配方计算器 | ||||
实验计算
动物体内配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
mg/kg
g
μL
只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
计算结果：
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；
体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。
体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。
注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
技术支持
在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。
如果有其他问题，请给我们留言。
* 必填项
Tags: buy Verapamil HCl | Verapamil HCl supplier | purchase Verapamil HCl | Verapamil HCl cost | Verapamil HCl manufacturer | order Verapamil HCl | Verapamil HCl distributor
